Literature DB >> 24581515

The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate.

Shinsuke Shibuya1, Zhang Xia2, Mikio Sugimoto2, Nobufumi Ueda2, Reiji Haba1, Yoshiyuki Kakehi3.   

Abstract

OBJECTIVE: To evaluate the effect of phytotherapeutic agent, Eviprostat, administered after the establishment of nonbacterial prostatitis (NBP) on the stroma-to-epithelium ratio (S/E ratio), inflammatory scores, tissue macrophage infiltration, and cytokines and chemokines levels in prostate tissue and urine.
MATERIALS AND METHODS: Ten-month-old male Wistar rats were castrated and exposed to 17-beta-isomer of estradiol for 30 days to induce NBP. Twenty-five NBP rats were divided into 5 groups: (1) NBP (0) rats sacrificed immediately after the establishment of NBP; (2,3) NBP (30)/control (CTL) and NBP (30)/Eviprostat (EVI) rats fed without or with 0.1% Eviprostat under estradiol-free for 30 days, respectively; and (4,5) NBP (60)/CTL and NBP (60)/EVI rats fed without or with 0.1% Eviprostat under estradiol-free for 60 days, respectively. The S/E ratio, inflammatory scores, and the number of macrophage infiltration in the prostate were assessed. Concentrations of cytokines and chemokines in prostatic tissue and urine were measured by enzyme-linked immunosorbent assay.
RESULTS: The S/E ratio was significantly increased with time until 60 days under estradiol-free condition (P <.001). The S/E ratio and the inflammatory scores in NBP (60)/EVI was significantly lower than that of NBP (60)/CTL (P <.001, and P = .022, respectively). The mean tissue concentration of chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) in NBP (60)/CTL was significantly higher than that in NBP (0) (P = .016), whereas, there was no difference between NBP (60)/EVI and NBP (0). Furthermore, urinary CCL2/MCP-1 was significantly decreased in NBP (60)/EVI as compared with NBP (0) (P = .028).
CONCLUSION: Eviprostat suppresses the stromal proliferation and inflammation in the rat prostate after the establishment of NBP at least partly owing to inhibitory effect on CCL2/MCP-1 production in the prostate.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24581515     DOI: 10.1016/j.urology.2013.11.033

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.

Authors:  Pradeep Tyagi; Saundra S Motley; Tatsuki Koyama; Mahendra Kashyap; Jeffrey Gingrich; Naoki Yoshimura; Jay H Fowke
Journal:  Prostate       Date:  2017-10-27       Impact factor: 4.104

2.  Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Xianjin Wang; Shan Zhong; Tianyuan Xu; Leilei Xia; Xiaohua Zhang; Zhaowei Zhu; Minguang Zhang; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2014-11-20       Impact factor: 2.370

Review 3.  Phytotherapy and physical therapy in the management of chronic prostatitis-chronic pelvic pain syndrome.

Authors:  Min Hu; Junaid Wazir; Rahat Ullah; Wenlu Wang; Xingxing Cui; Meng Tang; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2019-05-03       Impact factor: 2.370

Review 4.  The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia.

Authors:  Rikiya Taoka; Yoshiyuki Kakehi
Journal:  Asian J Urol       Date:  2017-05-25

5.  A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis.

Authors:  Mikio Sugimoto; Xia Zhang; Nobufumi Ueda; Hiroyuki Tsunemori; Rikiya Taoka; Yusi Hayashida; Hiromi Hirama; Yasuyuki Miyauchi; Yuki Matsuoka; Hirohito Naito; Yu Osaki; Yosiyuki Kekehi
Journal:  BMC Urol       Date:  2019-10-23       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.